Fischer medical ventures Limited has announced a strategic investment through its subsidiary in the Indonesian healthcare market. The company's wholly owned subsidiary, FMV Global Innovations Pte Limited, has acquired a 75% stake in PT Fischer Pariko Medical Ventures, marking the company's expansion into Southeast Asian markets.

Investment Structure and Details

The investment was formalized through a regulatory filing dated March 03, 2026, submitted to both BSE Limited and the National Stock Exchange of India under Regulation 30 of SEBI Listing Obligations and Disclosure Requirements Regulations, 2015. The transaction establishes PT Fischer Pariko Medical Ventures as a related party to Fischer Medical Ventures Limited through the subsidiary investment structure.

Target Company Profile

PT Fischer Pariko Medical Ventures operates in the healthcare sector, focusing on wholesale of medical, professional, scientific and precision equipment. The Indonesian company was incorporated on October 14, 2024, making it a recently established entity in the healthcare distribution space.

Regulatory Compliance and Structure

The investment transaction falls within the related party framework, as FMV Global Innovations Pte Limited is a 100% subsidiary of Fischer Medical Ventures Limited. The company has confirmed that no governmental or regulatory approvals were required for this acquisition, and no direct cash consideration was involved in the transaction.

The filing indicates that the objects and effects of acquisition, indicative time period for completion, and nature of consideration were marked as not applicable, suggesting this was a straightforward equity participation in the newly incorporated Indonesian entity. The investment aligns with Fischer Medical Ventures' core healthcare business operations, representing a natural extension of the company's existing medical equipment and healthcare services portfolio into international markets.

Fischer Medical Ventures Limited has disclosed the creation of a pledge by promoter Shankar Varadharajan involving 30,00,000 equity shares in favor of HDFC Bank Ltd. The disclosure was made on February 6, 2026, in compliance with Regulation 31(1) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Pledge Transaction Details

The pledge creation took place on February 5, 2026, covering 30,00,000 equity shares representing 4.63% of the company's total share capital. This transaction serves as collateral for a loan facility extended by HDFC Bank Ltd.

Promoter Holdings and Impact

Shankar Varadharajan holds a total of 69,00,15,30 equity shares in Fischer Medical Ventures Limited, representing 10.64% of the company's total share capital. The pledged shares constitute 43.48% of his total promoter shareholding in the company.

Financial Terms and Security Cover

The pledge arrangement involves a loan amount of ₹40 crores against pledged shares valued at ₹109.59 crores on the date of the transaction, providing a security cover ratio of 2.74 times the loan amount.

Fund Utilization

The borrowed amount of ₹40 crores will be utilized for working capital requirements of Fischer Medical Ventures' wholly owned subsidiary. According to the disclosure, this funding will ultimately strengthen group operations and consolidated performance, with no portion allocated for personal use by promoters.

Regulatory Compliance

The company has fulfilled its disclosure obligations under SEBI regulations, noting that while the encumbered shares represent less than 50% of promoter shareholding, they constitute more than 20% of the total share capital, triggering mandatory disclosure requirements. Fischer Medical Ventures Limited is listed on both BSE Limited (Scrip Code: 524743) and National Stock Exchange of India Limited (Scrip Symbol: FISCHER).